ID   HRA-19
AC   CVCL_2508
SY   HRA 19; HRA19
DR   cancercelllines; CVCL_2508
DR   ColonAtlas; HRA19
DR   Cosmic; 876723
DR   Cosmic; 948851
DR   Cosmic; 986014
DR   Cosmic; 995408
DR   Cosmic; 1043816
DR   Cosmic; 1312302
DR   Cosmic; 2301986
DR   Cosmic; 2760063
DR   Cosmic; 2800564
DR   ECACC; 10012802
DR   GEO; GSM1346842
DR   GEO; GSM1374548
DR   IARC_TP53; 21738
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Wikidata; Q54895214
DR   Ximbio; 152465
RX   PubMed=3569697;
RX   PubMed=3718830;
RX   PubMed=8197130;
RX   PubMed=9294210;
RX   PubMed=10737795;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=20606684;
RX   PubMed=23272949;
RX   PubMed=24755471;
RX   PubMed=29101300;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg405Ter (c.1213C>T); ClinVar=VCV000127275; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.42_45delTCTT); Zygosity=Heterozygous (PubMed=8197130).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=16418264; PubMed=24755471).
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: Ximbio; 152465; probable.
CC   Derived from site: In situ; Rectum; UBERON=UBERON_0001052.
ST   Source(s): ECACC
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 11
ST   D5S818: 11
ST   D7S820: 9,12
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 16
DI   NCIt; C9383; Rectal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   66Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=3569697; DOI=10.1111/j.1432-0436.1987.tb01551.x;
RA   Kirkland S.C.;
RT   "Endocrine differentiation by a human rectal adenocarcinoma cell line
RT   (HRA-19).";
RL   Differentiation 33:148-155(1986).
//
RX   PubMed=3718830; DOI=10.1038/bjc.1986.132;
RA   Kirkland S.C., Bailey I.G.;
RT   "Establishment and characterisation of six human colorectal
RT   adenocarcinoma cell lines.";
RL   Br. J. Cancer 53:779-785(1986).
//
RX   PubMed=8197130; DOI=10.1073/pnas.91.11.4751;
RA   Bicknell D.C., Rowan A.J., Bodmer W.F.;
RT   "Beta 2-microglobulin gene mutations: a study of established
RT   colorectal cell lines and fresh tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994).
//
RX   PubMed=9294210; DOI=10.1073/pnas.94.19.10330;
RA   Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.;
RT   "Beta-catenin mutations in cell lines established from human
RT   colorectal cancers.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//